Leerink Partnrs Issues Pessimistic Forecast for JNJ Earnings

Johnson & Johnson (NYSE:JNJ) – Research analysts at Leerink Partnrs lowered their FY2027 earnings per share (EPS) estimates for shares of Johnson & Johnson in a note issued to investors on Wednesday, October 16th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $10.73 per share for the year, down from their previous forecast of $11.71. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.00 per share. Leerink Partnrs also issued estimates for Johnson & Johnson’s FY2028 earnings at $11.70 EPS.

JNJ has been the topic of several other reports. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.12 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm’s 50-day moving average is $162.98 and its 200-day moving average is $154.69. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a market cap of $397.39 billion, a price-to-earnings ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $2.66 earnings per share.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the company. Violich Capital Management Inc. boosted its holdings in Johnson & Johnson by 0.6% in the third quarter. Violich Capital Management Inc. now owns 97,678 shares of the company’s stock valued at $15,830,000 after acquiring an additional 557 shares during the last quarter. Penn Davis Mcfarland Inc. bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $6,807,000. One Degree Advisors Inc acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $244,000. McClarren Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 12.6% during the third quarter. McClarren Financial Advisors Inc. now owns 1,152 shares of the company’s stock worth $187,000 after buying an additional 129 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Johnson & Johnson by 0.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 451,598 shares of the company’s stock valued at $73,186,000 after acquiring an additional 2,437 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.